vimarsana.com
Home
Live Updates
Genentech's BTK Inhibitor Fenebrutinib Significantly Reduced
Genentech's BTK Inhibitor Fenebrutinib Significantly Reduced
Genentech's BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
–– Fenebrutinib is an investigational, potent and highly selective oral Bruton’s tyrosine kinase inhibitor, the only reversible BTK inhibitor currently in Phase III multiple... | May 17, 2023
Related Keywords
United States ,
Levi Garraway ,
Roche Group ,
Genentech ,
Drug Administration ,
Global Product Development ,
Global Product ,
Important Safety ,
Multifocal Leukoencephalopathy ,
Ocrevus Pregnancy ,
Prescribing Information ,
Roche Holding Ag Stock Exchange ,
News ,
Information ,
Press Release ,
Fenebrutinib ,
Us ,
N ,
Kpotent ,
End ,
Ighly ,
Elective ,
Mural ,
Tyrosine ,
Inase ,
The ,
Only ,
Irreversible ,
Stk ,
Inhibitor ,
Currently ,
Hase ,
Ii Rog Ch0012032048 ,